Endocrine Adiponectin-FGF15/19 Axis in Ethanol-Induced Inflammation and Alcoholic Liver Injury.

Q2 Biochemistry, Genetics and Molecular Biology Gene expression Pub Date : 2018-05-18 Epub Date: 2017-11-02 DOI:10.3727/105221617X15093738210295

Min You, Zhou Zhou, Michael Daniels, Alvin Jogasuria

{"title":"Endocrine Adiponectin-FGF15/19 Axis in Ethanol-Induced Inflammation and Alcoholic Liver Injury.","authors":"Min You, Zhou Zhou, Michael Daniels, Alvin Jogasuria","doi":"10.3727/105221617X15093738210295","DOIUrl":null,"url":null,"abstract":"<p><p>Alcoholic liver disease (ALD) is the most prevalent form of liver disease, encompassing a spectrum of progressive pathological changes from steatosis to steatohepatitis to fibrosis/cirrhosis and hepatocellular carcinoma. Alcoholic steatosis/steatohepatitis is the initial stage of ALD and a major risk factor for advanced liver injuries. Adiponectin is a hormone secreted from adipocytes. Fibroblast growth factor (FGF) 15 (human homolog, FGF19) is an ileum-derived hormone. Adipocyte-derived adiponectin and gut-derived FGF15/19 regulate each other, share common signaling cascades, and exert similar beneficial functions. Emerging evidence has revealed that dysregulated adiponectin-FGF15/19 axis and impaired hepatic adiponectin-FGF15/19 signaling are associated with alcoholic liver damage in rodents and humans. More importantly, endocrine adiponectin-FGF15/19 signaling confers protection against ethanol-induced liver damage via fine tuning the adipose-intestine-liver crosstalk, leading to limited hepatic inflammatory responses, and ameliorated alcoholic liver injury. This review is focused on the recently discovered endocrine adiponectin-FGF15/19 axis that is emerging as an essential adipose-gut-liver coordinator involved in the development and progression of alcoholic steatohepatitis.</p>","PeriodicalId":12502,"journal":{"name":"Gene expression","volume":"18 2","pages":"103-113"},"PeriodicalIF":0.0000,"publicationDate":"2018-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3727/105221617X15093738210295","citationCount":"15","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gene expression","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3727/105221617X15093738210295","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2017/11/2 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}

引用次数: 15

Abstract

Alcoholic liver disease (ALD) is the most prevalent form of liver disease, encompassing a spectrum of progressive pathological changes from steatosis to steatohepatitis to fibrosis/cirrhosis and hepatocellular carcinoma. Alcoholic steatosis/steatohepatitis is the initial stage of ALD and a major risk factor for advanced liver injuries. Adiponectin is a hormone secreted from adipocytes. Fibroblast growth factor (FGF) 15 (human homolog, FGF19) is an ileum-derived hormone. Adipocyte-derived adiponectin and gut-derived FGF15/19 regulate each other, share common signaling cascades, and exert similar beneficial functions. Emerging evidence has revealed that dysregulated adiponectin-FGF15/19 axis and impaired hepatic adiponectin-FGF15/19 signaling are associated with alcoholic liver damage in rodents and humans. More importantly, endocrine adiponectin-FGF15/19 signaling confers protection against ethanol-induced liver damage via fine tuning the adipose-intestine-liver crosstalk, leading to limited hepatic inflammatory responses, and ameliorated alcoholic liver injury. This review is focused on the recently discovered endocrine adiponectin-FGF15/19 axis that is emerging as an essential adipose-gut-liver coordinator involved in the development and progression of alcoholic steatohepatitis.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

内分泌脂联素- fgf15 /19轴在乙醇诱导炎症和酒精性肝损伤中的作用

酒精性肝病(ALD)是最常见的肝脏疾病，包括一系列进行性病理变化，从脂肪变性到脂肪性肝炎到纤维化/肝硬化和肝细胞癌。酒精性脂肪变性/脂肪性肝炎是ALD的初始阶段，也是晚期肝损伤的主要危险因素。脂联素是一种由脂肪细胞分泌的激素。成纤维细胞生长因子(FGF) 15(人类同源物，FGF19)是一种来自回肠的激素。脂肪细胞衍生的脂联素和肠道衍生的FGF15/19相互调节，具有共同的信号级联，并发挥相似的有益功能。新出现的证据表明，脂联素- fgf15 /19轴失调和肝脂联素- fgf15 /19信号受损与啮齿动物和人类的酒精性肝损伤有关。更重要的是，内分泌脂联素- fgf15 /19信号通过微调脂肪-肠-肝串扰，保护肝脏免受乙醇诱导的肝损伤，导致有限的肝脏炎症反应，并改善酒精性肝损伤。本文综述了最近发现的内分泌脂联素- fgf15 /19轴，它是参与酒精性脂肪性肝炎发生和进展的重要脂肪-肠-肝协调者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Gene expression 生物-生物工程与应用微生物

CiteScore

3.80

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： Gene Expression, The Journal of Liver Research will publish articles in all aspects of hepatology. Hepatology, as a research discipline, has seen unprecedented growth especially in the cellular and molecular mechanisms of hepatic health and disease, which continues to have a major impact on understanding liver development, stem cells, carcinogenesis, tissue engineering, injury, repair, regeneration, immunology, metabolism, fibrosis, and transplantation. Continued research and improved understanding in these areas will have a meaningful impact on liver disease prevention, diagnosis, and treatment. The existing journal Gene Expression has expanded its focus to become Gene Expression, The Journal of Liver Research to meet this growing demand. In its revised and expanded scope, the journal will publish high-impact original articles, reviews, short but complete articles, and special articles (editorials, commentaries, opinions) on all aspects of hepatology, making it a unique and invaluable resource for readers interested in this field. The expanded team, led by an Editor-in-Chief who is uniquely qualified and a renowned expert, along with a dynamic and functional editorial board, is determined to make this a premier journal in the field of hepatology.